Welcome to our dedicated page for BIORA THERAPEUTICS news (Ticker: BIOR), a resource for investors and traders seeking the latest updates and insights on BIORA THERAPEUTICS stock.
Biora Therapeutics, Inc., formerly known as Progenity, Inc., is a clinical-stage biotechnology company focused on developing oral drug delivery technologies for gastrointestinal diseases and biologic therapies. The company operates two proprietary platforms: NaviCap for targeted delivery within the digestive tract and BioJet for systemic delivery of large molecule drugs.
Important Status Update: In December 2024, Biora Therapeutics filed for Chapter 11 bankruptcy protection. The company completed its restructuring and emerged in March 2025 as a privately held entity. Existing common shares were cancelled, and the company is no longer publicly traded on any stock exchange.
The NaviCap platform utilizes an ingestible capsule equipped with autolocation technology to deliver therapeutics directly to specific locations in the gastrointestinal tract. The lead program, BT-600, combines the NaviCap device with a liquid formulation of tofacitinib for treating moderate to severe ulcerative colitis. Clinical trials have evaluated the device's ability to localize within the colon and release medication at the intended site.
The BioJet platform aims to enable needle-free oral delivery of biologic drugs through liquid jet injection technology contained within a swallowable capsule. Development programs include BT-002, which delivers an adalimumab variant for inflammatory conditions, and BT-200, which delivers a GLP-1 receptor agonist for type 2 diabetes management. The company has established research collaborations with pharmaceutical partners to advance this technology.
Biora Therapeutics maintains an extensive intellectual property portfolio with over 30 patent families covering both platforms. The company's technology addresses challenges associated with delivering adequate drug concentrations to disease sites while minimizing systemic exposure and side effects. News related to Biora may cover clinical trial results, regulatory developments, partnership announcements, and advances in oral drug delivery technology.
FAQ
What is the current stock price of BIORA THERAPEUTICS (BIOR)?
What is the market cap of BIORA THERAPEUTICS (BIOR)?
